LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
1. LAVA Therapeutics announced dosing the first patient for LAVA-1266 study. 2. LAVA-1266 targets CD123+ tumors in AML and MDS patients. 3. Initial Phase 1 data read-out expected by year-end 2025. 4. Preclinical models show LAVA-1266's efficacy with limited off-target effects. 5. Emphasis on reduced toxicity compared to earlier CD123-targeted therapies.